US 12,152,241 B2
Targeting human satellite II (HSATII)
David T. Ting, Dover, MA (US); Daniel A. Haber, Chestnut Hill, MA (US); Shyamala Maheswaran, Lexington, MA (US); Francesca Bersani, Turin (IT); Anders M. Naar, Arlington, MA (US); Mihir Shivadatta Rajurkar, Worcester, MA (US); Sakari Kauppinen, Holte (DK); and Andreas Petri, Frederiksberg (DK)
Assigned to The General Hospital Corporation, Boston, MA (US); and Aalborg University, Aalborg (DK)
Filed by The General Hospital Corporation, Boston, MA (US); and Aalborg University, Aalborg (DK)
Filed on Apr. 24, 2019, as Appl. No. 16/393,557.
Application 16/393,557 is a continuation of application No. 15/321,391, granted, now 10,301,624, previously published as PCT/US2015/037792, filed on Jun. 25, 2015.
Claims priority of provisional application 62/017,012, filed on Jun. 25, 2014.
Prior Publication US 2020/0017856 A1, Jan. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); C12Q 1/6886 (2018.01)
CPC C12N 15/113 (2013.01) [C12Q 1/6886 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method of treating a subject with cancer, wherein the cancer expresses high levels of human satellite II (HSATII) RNA compared to a reference level, the method comprising administering:
(a) an isolated oligonucleotide of 13-30 nucleotides that hybridizes to the HSATII RNA wherein at least one nucleotide of the isolated oligonucleotide is modified or is a nucleotide analogue, wherein the isolated oligonucleotide is complementary to at least 17 consecutive nucleotides of SEQ ID NO: 1; is complementary to at least 12 consecutive nucleotides of SEQ ID NO: 2; is complementary to at least 24 consecutive nucleotides of SEQ ID NO: 3; is complementary to at least 17 consecutive nucleotides of SEQ ID NO: 4; or is complementary to at least 11 consecutive nucleotides of SEQ ID NO: 5; and
(b) a reverse transcriptase inhibitor.